NCT01642186View on ClinicalTrials.gov

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 12, 2012

Primary Completion Date

July 16, 2021

Study Completion Date

July 16, 2021

Conditions
Fibrolamellar CarcinomaFibrolamellar Liver Cancer
Interventions
DRUG

everolimus

DRUG

letrozole plus leuprolide

DRUG

combination of everolimus, letrozole and leuprolide

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

21287

John Hopkins Medical Center, Baltimore

94143

University of California San Francisco, San Francisco

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Fibrolamellar Cancer Foundation

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

University of California, San Francisco

OTHER

collaborator

Abbott

INDUSTRY

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER